Sai Life Sciences Ltd.
NSE: SAILIFE · Pharmaceuticals
Snapshot
Unlock Sai Life Sciences Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sai Life Sciences is a contract research, development, and manufacturing organisation (CRDMO) providing end-to-end services for the pharmaceutical and biotechnology industries. The company specialises in medicinal chemistry, pharmacokinetics, and contract development and manufacturing services.
Business Model
The company operates as a service provider, generating revenue through long-term partnerships with global pharmaceutical firms for drug discovery, development, and commercial-scale manufacturing. It leverages its research facilities and manufacturing infrastructure to support clients across the drug lifecycle.
- Incorporation Year:1999
Growth Outlook
Growth is driven by the increasing global trend of pharmaceutical companies outsourcing research and manufacturing to specialised Indian CRDMOs. The company continues to expand its service capabilities to capture a larger share of the drug development value chain.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and inspections by international health authorities like the US FDA.
- Client Concentration. Dependency on a limited number of large pharmaceutical clients can lead to significant revenue volatility if contracts are terminated or reduced.
- Intellectual Property Risk. As a service provider handling sensitive client data and proprietary compounds, any breach of intellectual property could result in severe legal and reputational damage.
- Geopolitical and Currency Risk. Operating internationally exposes the company to fluctuations in foreign exchange rates and potential changes in global trade policies.
Start your research today
Unlock AI insights, financials, peers and live data on Sai Life Sciences Ltd. and 5,000+ companies — free.
Key Metrics
P/E
92.3x
Q1 FY27 · consolidated
EV/EBITDA
48.0x
Q1 FY27 · consolidated
NET PROFIT MARGIN
13.2%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Sai Life Sciences Ltd.SAILIFE | ₹33,605 Cr | 92.27 | 47.96 | — | 31.2% | 15.7% | 19.8% | +86.7% |
Emcure Pharmaceuticals Ltd.EMCURE | ₹36,559 Cr | 36.13 | 18.90 | 18.4% | 20.6% | 21.7% | 27.3% | +40.6% |
Wockhardt Ltd.WOCKPHARMA | ₹33,940 Cr | 82.88 | 40.10 | 18.4% | 25.1% | 8.9% | 10.4% | +41.5% |
Rubicon ResearchRUBICON | ₹29,245 Cr | 99.68 | 63.32 | — | 23.9% | 22.4% | 27.6% | — |
Neuland Laboratories Ltd.NEULANDLAB | ₹29,073 Cr | 58.41 | 36.78 | 78.3% | 33.5% | 29.3% | 35.4% | +55.1% |
Piramal Pharma Ltd.PPLPHARMA | ₹28,520 Cr | -90.39 | 26.16 | 0.8% | 13.6% | -3.9% | 1.4% | +7.7% |
As of Q1 FY27
Financials
Sai Life Sciences Ltd.
NSE: SAILIFE · Pharmaceuticals
Snapshot
Unlock Sai Life Sciences Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sai Life Sciences is a contract research, development, and manufacturing organisation (CRDMO) providing end-to-end services for the pharmaceutical and biotechnology industries. The company specialises in medicinal chemistry, pharmacokinetics, and contract development and manufacturing services.
Business Model
The company operates as a service provider, generating revenue through long-term partnerships with global pharmaceutical firms for drug discovery, development, and commercial-scale manufacturing. It leverages its research facilities and manufacturing infrastructure to support clients across the drug lifecycle.
- Incorporation Year:1999
Growth Outlook
Growth is driven by the increasing global trend of pharmaceutical companies outsourcing research and manufacturing to specialised Indian CRDMOs. The company continues to expand its service capabilities to capture a larger share of the drug development value chain.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and inspections by international health authorities like the US FDA.
- Client Concentration. Dependency on a limited number of large pharmaceutical clients can lead to significant revenue volatility if contracts are terminated or reduced.
- Intellectual Property Risk. As a service provider handling sensitive client data and proprietary compounds, any breach of intellectual property could result in severe legal and reputational damage.
- Geopolitical and Currency Risk. Operating internationally exposes the company to fluctuations in foreign exchange rates and potential changes in global trade policies.
Start your research today
Unlock AI insights, financials, peers and live data on Sai Life Sciences Ltd. and 5,000+ companies — free.
Key Metrics
P/E
92.3x
Q1 FY27 · consolidated
EV/EBITDA
48.0x
Q1 FY27 · consolidated
NET PROFIT MARGIN
13.2%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27